ERBB2 and breast cancer: Beyond HER2 and ER/PR, new predictive biomarkers for targeted therapy in metastatic BC include BRCA1/2 and PI3KCA mutations for PARP and PI3KCA inhibitors, respectively, and PD-L1 expression and/or MSI status for immunotherapy.